NCT03808805CompletedPhase 3
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 63 (actual)
- First submitted
- 26 Sept 2018
- Start date
- 16 Apr 2019
- Primary completion date
- 1 Sept 2023
- Lead sponsor
- University Hospital, Brest
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT03808805
- EudraCT number
- 2018-000426-66
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 63
- From 16 Apr 2019 to the primary completion date, 1 Sept 2023
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with diffuse dermatological disease where pruritus may be present (psoriasis, atopic dermatitis, prurigo
- hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients
Other
- patients with a physical or psychological disability to sign the consent form
- patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but only treated by aspirin
- patients already included in another therapeutic protocol
- patients already on anti-anxiety and / or anti-depressant treatment
- patients with absolute contraindications to the use of Aprepitant or Hydroxyzine
- lactose intolerance
- pregnant or lactating women
Who the study is looking for
- Major patients with myeloproliferative neoplasms (polycythemia vera, essential thrombocythaemia or myelofibrosis)
- and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon, ruxolitinib or bled for more than 6 months
- and suffering of persistent aquagenic pruritus
- and with a pruritus intensity on Analogic Visual Scale \>5/10
- patients who gave their written consent for participation in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU d Angers Coordinator of this site? Confirm its status | Angers | France | Unknown status |
| CHRU de Brest - Hôpital Morvan Coordinator of this site? Confirm its status | Brest | France | Unknown status |
| CHU de CAEN Coordinator of this site? Confirm its status | Caen | France | Unknown status |
| Centre Hospitalier de Douarnenez Coordinator of this site? Confirm its status | Douarnenez | France | Unknown status |
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Unknown status |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
| Centre Hospitalier des Pays de Morlaix Coordinator of this site? Confirm its status | Morlaix | France | Unknown status |
| CHU de Nantes Coordinator of this site? Confirm its status | Nantes | France | Unknown status |
| Centre Hospitalier de Cornouaille Coordinator of this site? Confirm its status | Quimper | France | Unknown status |
| Hôpital Pontchaillou Coordinator of this site? Confirm its status | Rennes | France | Unknown status |
| Hôpital Yves Le Foll Coordinator of this site? Confirm its status | Saint-Brieuc | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.